Europe Allogeneic Human Chondrocyte Market Driven By High Prevalence of Musculoskeletal Injuries in Europe

 

Europe Allogeneic Human Chondrocyte

Allogeneic human chondrocyte is an emerging therapy that can be used for cartilage repair and other indications. It finds application in the treatment of musculoskeletal disorders and cartilage defects. It helps to reduce the risk of host-immune rejection due to its autologous nature and facilitates direct restoration of hyaline cartilage. Moreover, the therapy is less invasive and offers shorter recovery times compared to alternative, comparable therapies.

The Europe allogeneic human chondrocyte market is expected to witness significant growth, owing to high prevalence of musculoskeletal injuries in the region. According to the Study, ‘Prevalence of Musculoskeletal Injuries, Pain, and Illnesses in Elite Female Basketball Players, in Europe, in June 2019, the most frequently injured body parts were lower limbs: more than 60%, representing an injury rate of 0.14 per athletes and a 0.2 pain rate per athlete (during the study period).

Allogeneic human chondrocyte can be used in the treatment of osteoarthritis. According to the study ‘Osteoarthritis in Europe: Impact on health status, work productivity and use of pharmacotherapies in five European countries’ that examined the impact of peripheral joint osteoarthritis across five European countries, the U.K. (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high prevalence of peripheral joint osteoarthritis, with majority of cases aging 55-74 years. Such scenario suggests that high prevalence of osteoarthritis is expected to boost growth of the Europe allogeneic human chondrocyte market.  

The Europe allogeneic human chondrocyte market is also driven by partnership strategies among market players. For instance, in January 2020, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, signed sales agreement with Biosolution Co., Ltd, a Korea-based company focused on R&D in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region

The market for ureteral stents would benefit from the rising prevalence of urological diseases